From the clinic to the capital markets, here is Psychedelic Invest's roundup of the key headlines for the week of March 30 – April 5, 2026.
State of Texas (policy): Texas to run its own $50 million ibogaine clinical trial program
Lt. Governor Dan Patrick and House Speaker Dustin Burrows said Texas will deploy $50 million previously appropriated by the legislature to conduct its own ibogaine research program after the state failed to find a qualifying drug-company partner. Texas Health and Human Services selected UTHealth Houston, with UTMB Galveston, to lead a statewide two-year trial studying ibogaine for addiction, traumatic brain injury and other behavioral health conditions. The commitment is the largest single state investment in psychedelic research to date.
Source: ltgov.texas.gov
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.